Status:
UNKNOWN
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
B Cell Lymphocytic Leukemia
B Cell Non-Hodgkin's Lymphoma
Eligibility:
All Genders
Brief Summary
This is an observational cohort study of patients with a new diagnosis of B cell Chronic Lymphocytic Leukemia or B cell Non-Hodgkin's Lymphoma who will receive an anti-CD20 monoclonal antibody treatme...
Detailed Description
CMV infection results in a unique population of highly effective ADCC effector cells (g-NK) in more than 50% of individuals. Unlike most NK cells, g-NK cells are long-lived and persist for years follo...
Eligibility Criteria
Inclusion
- New diagnosis of CD20 expressing B-NHL or CLL
- o Up to 1/3rd of enrolled patients may have CLL. Enrollment of patients with CLL will be halted if this criterion is reached.
- Will receive an anti-CD20 monoclonal antibody treatment (including rituximab, obinatuzumab) during the induction phase of treatment
- Has not previously received cytotoxic chemotherapy medications
- Able to provide informed consent
Exclusion
- Comorbidities or frailty that would limit estimated survival to \<1 year.
- Will not receive active anti-CD20 containing remission induction therapy.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03417414
Start Date
March 1 2018
End Date
March 1 2021
Last Update
February 7 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.